 Maureen Leehey
Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 40 | 2021 | 117 | 4.940 |
Why?
| | Tremor | 34 | 2024 | 97 | 4.360 |
Why?
| | Fragile X Mental Retardation Protein | 36 | 2022 | 86 | 3.970 |
Why?
| | Parkinson Disease | 22 | 2024 | 556 | 3.410 |
Why?
| | Ataxia | 26 | 2021 | 70 | 3.030 |
Why?
| | Cannabidiol | 3 | 2024 | 123 | 1.570 |
Why?
| | Trinucleotide Repeat Expansion | 14 | 2022 | 44 | 1.260 |
Why?
| | Antiparkinson Agents | 6 | 2017 | 40 | 1.020 |
Why?
| | Cannabis | 2 | 2024 | 500 | 0.980 |
Why?
| | Heterozygote | 17 | 2016 | 305 | 0.930 |
Why?
| | Cognition Disorders | 9 | 2024 | 511 | 0.910 |
Why?
| | Dronabinol | 3 | 2024 | 238 | 0.890 |
Why?
| | Parkinsonian Disorders | 7 | 2016 | 43 | 0.830 |
Why?
| | Movement Disorders | 5 | 2016 | 64 | 0.740 |
Why?
| | Cognition | 5 | 2024 | 1179 | 0.650 |
Why?
| | Creatine | 2 | 2017 | 62 | 0.640 |
Why?
| | Mutation | 12 | 2021 | 3987 | 0.620 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 392 | 0.580 |
Why?
| | Double-Blind Method | 12 | 2024 | 1949 | 0.570 |
Why?
| | Metabolic Diseases | 1 | 2017 | 109 | 0.500 |
Why?
| | Aged | 52 | 2024 | 24024 | 0.470 |
Why?
| | Middle Aged | 58 | 2024 | 33604 | 0.460 |
Why?
| | Trinucleotide Repeats | 7 | 2011 | 31 | 0.450 |
Why?
| | Cannabinoids | 3 | 2022 | 168 | 0.420 |
Why?
| | Phenotype | 8 | 2021 | 3139 | 0.380 |
Why?
| | Cerebellar Ataxia | 3 | 2006 | 13 | 0.360 |
Why?
| | Severity of Illness Index | 11 | 2021 | 2851 | 0.360 |
Why?
| | Fibromyalgia | 1 | 2011 | 53 | 0.350 |
Why?
| | Male | 62 | 2024 | 68260 | 0.340 |
Why?
| | Point Mutation | 3 | 2007 | 236 | 0.340 |
Why?
| | Disease Progression | 8 | 2021 | 2749 | 0.330 |
Why?
| | Humans | 77 | 2024 | 138651 | 0.320 |
Why?
| | Genetic Carrier Screening | 4 | 2007 | 30 | 0.320 |
Why?
| | DNA Repeat Expansion | 2 | 2006 | 12 | 0.300 |
Why?
| | Female | 49 | 2024 | 73763 | 0.290 |
Why?
| | Levodopa | 5 | 2016 | 39 | 0.280 |
Why?
| | Memory Disorders | 4 | 2018 | 178 | 0.260 |
Why?
| | Central Nervous System Agents | 1 | 2006 | 6 | 0.260 |
Why?
| | Glutamate Decarboxylase | 3 | 2019 | 165 | 0.250 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2339 | 0.240 |
Why?
| | Gait Ataxia | 1 | 2005 | 5 | 0.240 |
Why?
| | Guidelines as Topic | 1 | 2007 | 272 | 0.240 |
Why?
| | Dopamine Agents | 2 | 2016 | 21 | 0.240 |
Why?
| | Treatment Outcome | 12 | 2024 | 10923 | 0.230 |
Why?
| | RNA-Binding Proteins | 6 | 2004 | 431 | 0.230 |
Why?
| | Magnetic Resonance Imaging | 14 | 2016 | 3637 | 0.220 |
Why?
| | Diagnostic Errors | 1 | 2005 | 174 | 0.210 |
Why?
| | Brain | 15 | 2016 | 2792 | 0.210 |
Why?
| | Neuropsychological Tests | 12 | 2020 | 1058 | 0.210 |
Why?
| | Age of Onset | 9 | 2016 | 514 | 0.210 |
Why?
| | Genetic Testing | 6 | 2011 | 451 | 0.210 |
Why?
| | Akinetic Mutism | 1 | 2003 | 3 | 0.200 |
Why?
| | Cerebral Arterial Diseases | 1 | 2003 | 49 | 0.190 |
Why?
| | Menopause | 2 | 2021 | 316 | 0.190 |
Why?
| | Genetic Therapy | 2 | 2017 | 314 | 0.190 |
Why?
| | Inosine | 1 | 2021 | 14 | 0.180 |
Why?
| | Pedigree | 7 | 2008 | 511 | 0.180 |
Why?
| | Dopamine Agonists | 2 | 2014 | 43 | 0.170 |
Why?
| | Dermatitis, Seborrheic | 1 | 2020 | 5 | 0.170 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2021 | 40 | 0.170 |
Why?
| | Uric Acid | 1 | 2021 | 165 | 0.160 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 2 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 138 | 0.160 |
Why?
| | Monoamine Oxidase Inhibitors | 2 | 2017 | 20 | 0.160 |
Why?
| | Nootropic Agents | 1 | 2020 | 29 | 0.160 |
Why?
| | Alleles | 4 | 2016 | 887 | 0.160 |
Why?
| | Sex Factors | 4 | 2011 | 2044 | 0.160 |
Why?
| | Ovary | 1 | 2021 | 223 | 0.150 |
Why?
| | Oxidoreductases | 1 | 2019 | 96 | 0.150 |
Why?
| | Nerve Tissue Proteins | 6 | 2004 | 600 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 555 | 0.140 |
Why?
| | RNA, Messenger | 9 | 2018 | 2815 | 0.140 |
Why?
| | Prodromal Symptoms | 1 | 2018 | 17 | 0.140 |
Why?
| | Adult | 23 | 2021 | 38201 | 0.140 |
Why?
| | Aged, 80 and over | 12 | 2016 | 7677 | 0.140 |
Why?
| | Urine | 1 | 2017 | 62 | 0.130 |
Why?
| | Syndrome | 5 | 2019 | 377 | 0.130 |
Why?
| | RNA, Transfer, Lys | 1 | 1995 | 3 | 0.120 |
Why?
| | Peripheral Nervous System Diseases | 2 | 2007 | 130 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 220 | 0.120 |
Why?
| | Family Health | 2 | 2007 | 194 | 0.120 |
Why?
| | Connectome | 1 | 2016 | 87 | 0.120 |
Why?
| | Dementia | 3 | 2006 | 261 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2019 | 898 | 0.110 |
Why?
| | Choice Behavior | 1 | 2016 | 172 | 0.110 |
Why?
| | Gene Transfer Techniques | 2 | 2017 | 176 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2019 | 706 | 0.110 |
Why?
| | Cerebellum | 3 | 2006 | 218 | 0.110 |
Why?
| | Memantine | 1 | 2014 | 14 | 0.110 |
Why?
| | Ubiquinone | 1 | 2014 | 31 | 0.110 |
Why?
| | Executive Function | 2 | 2009 | 453 | 0.100 |
Why?
| | Genetic Association Studies | 1 | 2015 | 370 | 0.100 |
Why?
| | Nerve Net | 1 | 2016 | 268 | 0.100 |
Why?
| | Aging | 3 | 2018 | 1855 | 0.100 |
Why?
| | Time Factors | 6 | 2020 | 6851 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 3256 | 0.100 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2844 | 0.100 |
Why?
| | Mitochondria | 2 | 1997 | 955 | 0.100 |
Why?
| | Multiple Sclerosis | 2 | 2009 | 460 | 0.100 |
Why?
| | Nucleic Acid Conformation | 1 | 1995 | 722 | 0.090 |
Why?
| | DNA Mutational Analysis | 4 | 2007 | 398 | 0.090 |
Why?
| | Neurons | 4 | 2005 | 1601 | 0.090 |
Why?
| | Intelligence | 5 | 2018 | 129 | 0.090 |
Why?
| | Neurologic Examination | 3 | 2008 | 128 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2007 | 1482 | 0.090 |
Why?
| | Autoantibodies | 1 | 2019 | 1456 | 0.090 |
Why?
| | Spinocerebellar Degenerations | 2 | 2007 | 7 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5112 | 0.080 |
Why?
| | Antioxidants | 1 | 2014 | 593 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 91 | 0.080 |
Why?
| | Conversion Disorder | 1 | 2009 | 9 | 0.080 |
Why?
| | Atrophy | 3 | 2005 | 189 | 0.080 |
Why?
| | Neuroimaging | 1 | 2012 | 263 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3523 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2016 | 858 | 0.080 |
Why?
| | Odds Ratio | 1 | 2011 | 1044 | 0.070 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2008 | 3 | 0.070 |
Why?
| | Selegiline | 1 | 2007 | 5 | 0.070 |
Why?
| | Body Mass Index | 1 | 2016 | 2349 | 0.070 |
Why?
| | Hypokinesia | 1 | 2007 | 11 | 0.070 |
Why?
| | Carbidopa | 1 | 2006 | 9 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2007 | 75 | 0.060 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 38 | 0.060 |
Why?
| | Huntington Disease | 1 | 2007 | 63 | 0.060 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2005 | 4 | 0.060 |
Why?
| | Activities of Daily Living | 1 | 2009 | 421 | 0.060 |
Why?
| | Problem Solving | 1 | 2007 | 156 | 0.060 |
Why?
| | Gene Silencing | 1 | 2007 | 196 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2014 | 15909 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2006 | 154 | 0.060 |
Why?
| | Prion Diseases | 1 | 2005 | 16 | 0.060 |
Why?
| | Paraparesis, Spastic | 1 | 2005 | 3 | 0.060 |
Why?
| | Memory, Short-Term | 3 | 2018 | 257 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2006 | 228 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2007 | 243 | 0.060 |
Why?
| | Prions | 1 | 2005 | 51 | 0.060 |
Why?
| | Motor Activity | 3 | 2020 | 710 | 0.050 |
Why?
| | Brain Tissue Transplantation | 1 | 2003 | 20 | 0.050 |
Why?
| | Fetal Tissue Transplantation | 1 | 2003 | 36 | 0.050 |
Why?
| | Astrocytes | 1 | 2005 | 216 | 0.050 |
Why?
| | Subthalamic Nucleus | 2 | 2017 | 78 | 0.050 |
Why?
| | Health Surveys | 1 | 2005 | 504 | 0.050 |
Why?
| | Intellectual Disability | 1 | 2005 | 168 | 0.050 |
Why?
| | Seizures | 1 | 2007 | 431 | 0.050 |
Why?
| | Anxiety Disorders | 1 | 2006 | 377 | 0.050 |
Why?
| | Verbal Learning | 3 | 2008 | 66 | 0.050 |
Why?
| | Administration, Oral | 2 | 2020 | 788 | 0.050 |
Why?
| | Gyrus Cinguli | 1 | 2003 | 93 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2030 | 0.050 |
Why?
| | Guanine | 1 | 2022 | 81 | 0.050 |
Why?
| | Functional Laterality | 1 | 2003 | 232 | 0.050 |
Why?
| | Regression Analysis | 2 | 2018 | 1017 | 0.050 |
Why?
| | Gene Expression | 1 | 2007 | 1488 | 0.040 |
Why?
| | Genetic Background | 1 | 2021 | 12 | 0.040 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 59 | 0.040 |
Why?
| | Eye Movements | 1 | 2021 | 82 | 0.040 |
Why?
| | Kidney Calculi | 1 | 2021 | 36 | 0.040 |
Why?
| | Placebos | 2 | 2014 | 198 | 0.040 |
Why?
| | Treatment Failure | 1 | 2021 | 351 | 0.040 |
Why?
| | Animals, Genetically Modified | 1 | 2021 | 242 | 0.040 |
Why?
| | Brain Diseases | 1 | 2001 | 148 | 0.040 |
Why?
| | Time and Motion Studies | 1 | 2020 | 26 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 448 | 0.040 |
Why?
| | Fertility | 1 | 2021 | 163 | 0.040 |
Why?
| | Bell Palsy | 1 | 1999 | 9 | 0.040 |
Why?
| | Attention | 2 | 2018 | 443 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 14 | 0.040 |
Why?
| | Drosophila melanogaster | 1 | 2021 | 232 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 1518 | 0.040 |
Why?
| | Treatment Refusal | 1 | 1999 | 96 | 0.040 |
Why?
| | Educational Status | 2 | 2016 | 462 | 0.040 |
Why?
| | Recovery of Function | 1 | 2003 | 665 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 1032 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2014 | 561 | 0.040 |
Why?
| | Mental Processes | 2 | 2008 | 35 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 25 | 0.030 |
Why?
| | Parvovirinae | 1 | 2017 | 5 | 0.030 |
Why?
| | Postural Balance | 1 | 2020 | 217 | 0.030 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1997 | 55 | 0.030 |
Why?
| | United States | 4 | 2017 | 14938 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2018 | 252 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5697 | 0.030 |
Why?
| | Stroke | 1 | 2005 | 1136 | 0.030 |
Why?
| | Electron Transport | 1 | 1997 | 116 | 0.030 |
Why?
| | Dependovirus | 1 | 2017 | 75 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1997 | 288 | 0.030 |
Why?
| | Motivation | 1 | 2001 | 591 | 0.030 |
Why?
| | National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2016 | 6 | 0.030 |
Why?
| | Mental Disorders | 1 | 2005 | 1096 | 0.030 |
Why?
| | Birefringence | 1 | 1995 | 7 | 0.030 |
Why?
| | Nucleic Acid Heteroduplexes | 1 | 1995 | 9 | 0.030 |
Why?
| | Reaction Time | 1 | 2018 | 421 | 0.030 |
Why?
| | Anticodon | 1 | 1995 | 25 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 304 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 336 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 591 | 0.030 |
Why?
| | Hypotension, Orthostatic | 1 | 2014 | 10 | 0.030 |
Why?
| | Canada | 1 | 2016 | 407 | 0.030 |
Why?
| | Cerebral Ventricles | 2 | 2006 | 54 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7554 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2006 | 5520 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 1374 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1765 | 0.030 |
Why?
| | Registries | 1 | 2022 | 2073 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 433 | 0.030 |
Why?
| | Animals | 2 | 2021 | 37217 | 0.030 |
Why?
| | Prevalence | 2 | 2014 | 2727 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 320 | 0.030 |
Why?
| | Blood Platelets | 1 | 1997 | 427 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2014 | 239 | 0.020 |
Why?
| | Video Recording | 1 | 2014 | 181 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1482 | 0.020 |
Why?
| | Base Sequence | 1 | 1995 | 2174 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3433 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 2923 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 1997 | 564 | 0.020 |
Why?
| | Hypertension | 1 | 1999 | 1242 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2065 | 0.020 |
Why?
| | Medication Adherence | 1 | 2015 | 504 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4092 | 0.020 |
Why?
| | Risk Factors | 2 | 2021 | 10252 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2049 | 0.020 |
Why?
| | RNA | 1 | 1995 | 925 | 0.020 |
Why?
| | Genotype | 2 | 2004 | 1842 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2009 | 299 | 0.020 |
Why?
| | Semantics | 1 | 2008 | 95 | 0.020 |
Why?
| | Tablets | 1 | 2007 | 41 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 105 | 0.020 |
Why?
| | Multiple System Atrophy | 1 | 2006 | 8 | 0.020 |
Why?
| | Association Learning | 1 | 2007 | 63 | 0.020 |
Why?
| | Education | 1 | 2007 | 108 | 0.020 |
Why?
| | Polypharmacy | 1 | 2007 | 88 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 100 | 0.020 |
Why?
| | Memory | 1 | 2008 | 258 | 0.020 |
Why?
| | Wechsler Scales | 1 | 2006 | 55 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2007 | 375 | 0.010 |
Why?
| | Personality Inventory | 1 | 2006 | 144 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 325 | 0.010 |
Why?
| | Bias | 1 | 2006 | 226 | 0.010 |
Why?
| | Adolescent | 2 | 2019 | 21564 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 2003 | 68 | 0.010 |
Why?
| | Transplants | 1 | 2003 | 38 | 0.010 |
Why?
| | Genetic Counseling | 1 | 2004 | 79 | 0.010 |
Why?
| | Videotape Recording | 1 | 2003 | 39 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 373 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1317 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2003 | 236 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 13305 | 0.010 |
Why?
| | Inclusion Bodies | 1 | 2002 | 28 | 0.010 |
Why?
| | Cerebellar Diseases | 1 | 2002 | 24 | 0.010 |
Why?
| | Cerebellar Cortex | 1 | 2002 | 21 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1233 | 0.010 |
Why?
| | California | 1 | 2004 | 436 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2003 | 184 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 310 | 0.010 |
Why?
| | Genetic Markers | 1 | 2002 | 342 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2002 | 309 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2007 | 770 | 0.010 |
Why?
| | Central Nervous System | 1 | 2003 | 263 | 0.010 |
Why?
| | Gait | 1 | 2004 | 303 | 0.010 |
Why?
| | Dopamine | 1 | 2003 | 308 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 841 | 0.010 |
Why?
| | Brain Mapping | 1 | 2003 | 524 | 0.010 |
Why?
| | Facial Nerve | 1 | 1999 | 39 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2002 | 607 | 0.010 |
Why?
| | Patient Selection | 1 | 2003 | 676 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 819 | 0.010 |
Why?
| | Mass Screening | 1 | 2007 | 1292 | 0.010 |
Why?
| | Neurofibrils | 1 | 1997 | 2 | 0.010 |
Why?
| | Electron Transport Complex III | 1 | 1997 | 19 | 0.010 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 1997 | 33 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1997 | 60 | 0.010 |
Why?
| | Electron Transport Complex IV | 1 | 1997 | 60 | 0.010 |
Why?
| | Child | 2 | 2006 | 21921 | 0.010 |
Why?
| | Reference Values | 1 | 1997 | 799 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2698 | 0.000 |
Why?
|
|
Leehey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|